Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.24), $0.13 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.